Human Biglycan Antibody

Biglycan in Human Kidney Array.

Biglycan was detected in immersion fixed paraffin-embedded sections of human kidney array using Human Biglycan Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2667) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of Mouse Biglycan by Immunocytochemistry/Immunofluorescence

LDL binding to the vessel wall in vitro following treatment with Site B peptide or enzymatic digestion of proteoglycan GAG chains. Tissue sections of carotid arteries from wild‐type mice with intimal hyperplasia were incubated with human LDL. Bound LDL was detected using anti‐apoB antibody. (A) LDL binding to tissue sections pre‐incubated with positively charged SiteB peptide (white circles) or neutrally charged SiteB KE peptide (gray circles). Black circles=no pre‐treatment. White triangles=no LDL incubation (buffer only). (B) LDL binding to tissue sections pre‐treated with the GAG‐degrading enzymes chondroitinase (white circles) or heparinase (white dot circles). Black circles=no pre‐treatment. White triangles=no LDL incubation (buffer only). Data was analyzed using Mann–Whitney rank sum test. Graph bars show median values. P < 0.05 is regarded significant, n = 5–8 in each group. (C) Multi‐immunostaining for biglycan (red, left panels) and perlecan (green, right panels) of tissue sections from the injured region (upper panels) and the uninjured region (lower panels) 3 weeks after carotid injury in a wild‐type mouse. Nuclei are stained with DAPI (blue). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28716818), licensed under a CC-BY license. Not internally tested by R&D Systems.